Goldman Sachs Maintains Buy on Viridian Therapeutics, Lowers Price Target to $27

Benzinga · 05/07 17:11
Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $31 to $27.